Results 121 to 130 of about 140,845 (265)

Human Rhinovirus A16 Infection of Mast Cells Promotes T2 and Non‐T2 Immune Responses That Are Modulated by the Airway Epithelium

Allergy, EarlyView.
Ying Lai, Ryan C. Murphy, Matthew Liu, Maciej W. Czarnecki, Dane Grosvenor, Kimberly A. Dill‐McFarland, Adrian M. Piliponsky, Jason S. Debley, Matthew C. Altman, Teal S. Hallstrand   +9 more
wiley   +1 more source

Clonal expansion of global pneumococcal sequence cluster 3 within serotype 8 after 13-valent pneumococcal conjugate vaccine introduction, South Africa. [PDF]

Microb Genom
Lekhuleni C, Ndlangisa K, Sanches Ferreira AD, Cheng HR, Lorenz O, Kleynhans J, de Gouveia L, Skosana H, Quan V, Cremers AJH, Hawkins PA, Chochua S, McGee L, Bentley SD, Meiring S, Cohen C, Lo SW, von Gottberg A, du Plessis M.   +18 more
europepmc   +1 more source

Bringing Gene Therapy Into Real World Clinical Practice

Haemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach, Pratima Chowdary, Margareth C. Ozelo   +2 more
wiley   +1 more source

The need for balanced dengue vaccine protection: Insights from Thai surveillance data on four serotypes. [PDF]

PLoS Negl Trop Dis
Khosavanna RR, Iamsirithaworn S, Pinpaiboon S, Phutthasophit K, Hunsawong T, Ko AI, Anderson KB, Buddhari D.   +7 more
europepmc   +1 more source

Gene Editing for Haemophilia—The Next Frontier

Haemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti, Gregory A. Newby, Sundar Selvaraj, Steven W. Pipe   +3 more
wiley   +1 more source

Invasive Pneumococcal Disease burden, clinical characteristics, serotypes' distribution, immunization status and antimicrobial resistance: Evidence from 12-year hospital-based surveillance and cost analysis. [PDF]

Hum Vaccin Immunother
Vecchio R, Iskandar E, Gentile L, Bertuccio P, Daprai L, Cambieri P, Muzzi A, Deandrea S, Riboli S, Cecconami L, Cereda D, Baldanti F, Odone A.   +12 more
europepmc   +1 more source

Will Extended‐Valency Pneumococcal Conjugate Vaccines Offer Enhanced Coverage Against Invasive Pneumococcal Disease for At‐Risk Children?

Acta Paediatrica, EarlyView.
Robert Cohen, Corinne Levy, Naim Ouldali, Stéphane Béchet, Aude Estivaux, André Birgy, Isabelle Hau, IPD Study Group, Emmanuelle Varon   +8 more
wiley   +1 more source

Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Valoctocogene roxaparvovec is an adeno‐associated virus vector serotype 5 (AAV5)‐mediated gene therapy for severe haemophilia A (HA). Aim Report the final safety and efficacy results of the phase 1/2 trial of valoctocogene roxaparvovec. Methods An open‐label phase 1/2 trial (NCT02576795) enrolled adult males with severe HA (factor
Priyanka Raheja, Savita Rangarajan, Will Lester, Bella Madan, Glenn F. Pierce, Emily Symington, Carolyn Millar, Dane Osmond, Mingjin Li, Konstantia‐Maria Chavele   +9 more
wiley   +1 more source

Pneumococcal Serotypes and Virulence [PDF]

The Journal of Infectious Diseases, 2006
openaire   +2 more sources

Distribution of <i>Streptococcus pneumoniae</i> Serotypes in Nasopharyngeal Carriage Among Children in Indonesia and Estimated Coverage of Pneumococcal Conjugate Vaccines: A Systematic Review. [PDF]

Vaccines (Basel)
Prayitno A, Karyanti MR, Putri ND, Wicaksana P, Felicia F, Ninditya S, Kemalasari S, Ardine A, Satari HI, Hadinegoro SR.   +9 more
europepmc   +1 more source